Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 14/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | PAK4 | O96013 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.39 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9104806 | 0.80 | AHR (0.61) | AHRPIK3CGPIK3CDPIK3CA | |
| SCHEMBL15774157 | 0.77 | PIK3CG (0.47) | PIK3CGPIK3CDPIK3CBPIK3CAPAK4 | |
| SCHEMBL27037213 | 0.77 | CYP11B1 (0.46) | AHRPIK3CGPIK3CDPIK3CBPIK3CA | |
| SCHEMBL15537648 | 0.77 | PIK3CG (0.44) | AHRPIK3CGPIK3CDPIK3CBPIK3CA | |
| SCHEMBL20641321 | 0.77 | PIK3CG (0.44) | AHRPIK3CGPIK3CDPIK3CBPIK3CA | |
| SCHEMBL31096177 | 0.77 | AHR (0.57) | AHR | |
| SCHEMBL27038051 | 0.77 | AHR (0.57) | AHR | |
| SCHEMBL616699 | 0.77 | AHR (0.57) | AHRPIK3CGPIK3CDPIK3CA | |
| Bromide SCHEMBL23356680 | 0.76 | PIK3CG (0.43) | AHRPIK3CGPIK3CDPIK3CBPIK3CA | |
| SCHEMBL23761284 | 0.74 | PIK3CG (0.43) | AHRPIK3CGPIK3CDPIK3CBPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120476110-B | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | SHANGHAI HANSOH BIOMEDICAL Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-122071464-A | Heterocyclic compound, pharmaceutical composition thereof and application thereof | 上海璎黎药业有限公司 | 2026-05-22 | — | — | CN | disclosed |
| EP-4741376-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-12612403-B2 | Nitrogen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| US-12509455-B2 | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250388578-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-12-25 | — | — | US | disclosed |
| US-20250197390-A1 | FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| CN-119998271-A | Pyridone compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025096061-A1 | CDK2 INHIBITORS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010007100-A1 | 7-SUBSTITUTED AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LTD (GB) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007100-A1 | 7-SUBSTITUTED AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LTD (GB) | 2010-01-21 | — | — | WO | disclosed |
| US-7524860-B2 | Antibacterial agents | PFIZER INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524860-B2 | Antibacterial agents | PFIZER INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20080021059-A1 | Antibacterial Agents | PFIZER INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021059-A1 | Antibacterial Agents | PFIZER INC. (US) | 2008-01-24 | — | — | US | disclosed |
| EP-1799680-A2 | TRIAZOLOPYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006038116-A2 | TRIAZOLOPYRIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612403-B2 | Nitrogen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof | FAR1, NPR1, CBR1 | AHR 265/4885PIK3CG 1740/4885PIK3CD 2006/4885 |
| US-20250388578-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | FAR1, NPR1, CBR1 | AHR 265/4885PIK3CG 1740/4885PIK3CD 2006/4885 |
| US-20250197390-A1 | FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | RIPK1, RIPK4, MLKL | AHR 2460/4885PIK3CG 413/4885PIK3CD 338/4885 |
| US-12509455-B2 | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof | JAK1, JAK2, JAK3 | AHR 777/4885PIK3CG 987/4885PIK3CD 438/4885 |
| US-20080021059-A1 | Antibacterial Agents | CLPP, QDPR, CLSPN | AHR 3441/4885PIK3CG 1002/4885PIK3CD 806/4885 |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | AHR 617/4885PIK3CG 3467/4885PIK3CD 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.